decor-right

Our Unique Story

Gritstone is developing targeted immunotherapies for cancer and infectious disease. Gritstone’s approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens, and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients. To learn more about Gritstone's approach, please view the video below.

Meet Gritstone:

Gritstone is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts and Pleasanton, California. We were founded in August 2015 and are listed on the Nasdaq Global Select Market under the ticker symbol GRTS.

Our Leadership

To deliver on the promise of our novel therapeutic approaches, we have assembled an experienced leadership team with deep expertise in each of our core disciplines of immunotherapy research, genomics and bioinformatics, clinical and regulatory development, and biomanufacturing.

View Bio
Andrew Allen, M.D., Ph.D.

Co-founder, President and Chief Executive Officer

View Bio
Matthew Hawryluk, Ph.D.

Executive Vice President and Chief Business Officer

View Bio
Erin E. Jones, M.S.

Chief Operating Officer

View Bio
Karin Jooss, Ph.D.

Head of Research & Development

View Bio
Raphaël F. Rousseau, M.D., Ph.D.

Executive Vice President and Chief Medical Officer

View Bio
Rahsaan W. Thompson, J.D.

Executive Vice President and General Counsel

View Bio
Vijay Yabannavar, Ph.D.

Executive Vice President, Chief Manufacturing and Technical Operations Officer

View Bio
Roman Yelensky, Ph.D.

Executive Vice President and Chief Technology Officer

Board
of Directors

Andrew Allen, M.D., Ph.D.
Co-founder, President and Chief Executive Officer
Richard A. Heyman, Ph.D.
Executive Chairman and co-founder of Metacrine
Steve Krognes
Chief Financial Officer of Denali Therapeutics
Judith J. Li
Partner at Lilly Asia Ventures (LAV)
Elaine V. Jones, Ph.D.
Nicholas Simon
Senior Managing Director at Blackstone Life Sciences
Tom Woiwode, Ph.D.
Managing Director at Versant Ventures

Scientific
Advisory Board

Timothy A. Chan, M.D. Ph.D.
Eugene Zhukovsky, Ph.D.
James L. Gulley, M.D., Ph.D.
Graham Lord, M.D., Ph.D.
Naiyer A. Rizvi, M.D.
Jean-Charles Soria, M.D., Ph.D.
Alessandro Sette, Dr.Biol.Sci.
Top